Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2021;32(1):6-14
Article Links
Non-Invasive Assessment of Endothelial Dysfunction in Pulmonary Arterial Hypertension
Athanasia Dara1, Alexandra Arvanitaki1,2,3, Marieta Theodorakopoulou4, Christos Athanasiou1, Eleni Pagkopoulou1, Afroditi Boutou5
Authors Information

1. Fourth Department of Internal Medicine, Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

2. First Department of Cardiology, AHEPA University Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

3. Adult Congenital Heart Centre and National Centre for Pulmonary Arterial Hypertension, Royal Brompton  Hospital, Guy's and St Thomas' NHS Foundation Trust, Imperial College, London, United Kingdom

4. Department of Internal Medicine, General Hospital of Giannitsa, Giannitsa, Greece 

5. Department of Respiratory Medicine, G. Papanikolaou Hospital, Thessaloniki, Greece

Arvanitaki A, Pagkopoulou E 

Keywords: Pulmonary arterial hypertension, microvasculature, endothelial dysfunction, flow mediated dilation, arterial stiffness, nailfold videocapillaroscopy, near-infrared spectroscopy, magnetic resonance perfusion imaging, biochemical markers
References
  1. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019 Jan 24;53(1):1801913.
  2. Arvanitaki A, Boutsikou M, Anthi A, Apostolopoulou S, Avgeropoulou A, Demerouti E, et al. Epidemiology and initial management of pulmonary arterial hypertension: real-world data from the Hellenic pulmOnary hyPertension rEgistry (HOPE). Pulm Circ 2019;9:2045894019877157.
  3. Shahane A. Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis. Rheumatol Int 2013;33:1655-67.
  4. Dorfmuller P, Perros F, Balabanian K and Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358-63.
  5. Yeo PP and Sinniah R. Lupus cor pulmonale with electron microscope and immunofluroescent antibody studies. Ann Rheum Dis 1975;34:457-60.
  6. Yasuoka H, Shirai Y, Tamura Y, Takeuchi T and Kuwana M. Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Circ J 2018;82:546-54. DOI:
  7. Tuder RM. Pulmonary vascular remodeling in pulmonary hypertension. Cell Tissue Res 2017;367:643-9.
  8. Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 2001;195:367-74.
  9. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:261-72.
  10. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999;155:411-9.
  11. Rabinovitch M, Guignabert C, Humbert M and Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res 2014;115:165-75.
  12. Hughes R, Tong J, Oates C, Lordan J, Corris PA. Evidence for systemic endothelial dysfunction in patients and first-order relatives with pulmonary arterial hypertension. Chest 2005;128:617S.
  13. Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 2011 Nov;31(11):1409-17.
  14. Peled N, Bendayan D, Shitrit D, Fox B, Yehoshua L, Kramer MR. Peripheral endothelial dysfunction in patients with pulmonary arterial hypertension. Respir Med 2008;102:1791-6.
  15. Peled N, Shitrit D, Fox BD, Shlomi D, Amital A, Bendayan D, et al. Peripheral arterial stiffness and endothelial dysfunction in idiopathic and scleroderma associated pulmonary arterial hypertension. J Rheumatol 2009;36:970-5.
  16. Wolff B, Lodziewski S, Bollmann T, Opitz CF, Ewert R. Impaired peripheral endothelial function in severe idiopathic pulmonary hypertension correlates with the pulmonary vascular response to inhaled iloprost. Am Heart J 2007 Jun;153(6):1088.e1-7.
  17. Zimmermann R, Kreuder J, Michel-Behnke I, Voelkel NF, Schranz D. Pulmonary flow reserve in children with idiopathic pulmonary arterial hypertension: implications for diagnosis and therapy. Eur J Med Res 2006;11:208-13.
  18. Ilsar R, Chawantanpipat C, Chan KH, Dobbins TA, Waugh R, Hennessy A, et al. Measurement of pulmonary flow reserve and pulmonary index of microcirculatory resistance for detection of pulmonary microvascular obstruction. PLoS One 2010;5:e9601.
  19. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737-47.
  20. Smith V, Vanhaecke A, Herrick AL, Distler O, Guerra MG, Denton CP, et al. Fast track algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern". Autoimmun Rev 2019 Nov;18(11):102394.
  21. Soulaidopoulos S, Triantafyllidou E, Garyfallos A, Kitas GD, Dimitroulas T. The role of nailfold capillaroscopy in the assessment of internal organ involvement in systemic sclerosis: A critical review. Autoimmun Rev 2017;16:787-95.
  22. Arvanitaki A, Giannakoulas G, Triantafyllidou E, Karvounis H, Garyfallos A, Kitas G, et al. Nailfold videocapillaroscopy: a novel possible surrogate marker for the evaluation of peripheral microangiopathy in pulmonary arterial hypertension. Scand J Rheumatol 2020 Sep 10;1-10.
  23. Riccieri V, Vasile M, Iannace N, Stefanantoni K, Sciarra I, Vizza CD, et al. Systemic sclerosis patients with and without pulmonary arterial hypertension: a nailfold capillaroscopy study. Rheumatology (Oxford) 2013;52:1525-8.
  24. Ohtsuka T, Hasegawa A, Nakano A, Yamakage A, Yamaguchi M, Miyachi Y. Nailfold capillary abnormality and pulmonary hypertension in systemic sclerosis. Int J Dermatol 1997;36:116-22.
  25. Smith V, Riccieri V, Pizzorni C, Decuman S, Deschepper E, Bonroy C, et al. Nailfold capillaroscopy for prediction of novel future severe organ involvement in systemic sclerosis. J Rheumatol 2013;40:2023-8.
  26. Xia Z, Wang G, Xiao H, Guo S, Liu Y, Meng F, et al. Diagnostic value of nailfold videocapillaroscopy in systemic sclerosis secondary pulmonary arterial hypertension: a meta-analysis. Internal Medicine Journal 2018;48:1355-9.
  27. Corrado A, Correale M, Mansueto N, Monaco I, Carriero A, Mele A, et al. Nailfold capillaroscopic changes in patients with idiopathic pulmonary arterial hypertension and systemic sclerosis-related pulmonary arterial hypertension. Microvasc Res 2017;114:46-51.
  28. Hofstee HM, Vonk Noordegraaf A, Voskuyl AE, Dijkmans BA, Postmus PE, Smulders YM, et al. Nailfold capillary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis. Ann Rheum Dis 2009;68:191-5.
  29. Arvanitaki A, Giannakoulas G, Triantafyllidou E, Feloukidis C, Garyfallos A, Karvounis H, et al. Assessment of peripheral microvascular changes in Eisenmenger syndrome: A nailfold video capillaroscopy study. In: 12th Advanced Symposium on Adult Congenital Heart Disease. Virtual Conference. 21-22 September 2020, London, UK.
  30. Arvanitaki A, Giannakoulas G, Triantafyllidou E, Feloukidis C, Boutou AK, Garyfallos A, et al. Peripheral microangiopathy in precapillary pulmonary hypertension: a nailfold video capillaroscopy prospective study. Respiratory Research 2021;22.
  31. Arvanitaki A, Giannakoulas G, Triantafyllidou E, Karvounis H, Dimitroulas T. Peripheral Microangiopathy in Patients with Precapillary Pulmonary Hypertension: Correlation with Cardiac Function and Patients' Functional Capacity. Study Design and Rationale. Mediterr J Rheumatol 2020;31:369-73.
  32. Kielstein JT, Bode-Boger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005;25:1414-8.
  33. Boushel R, Langberg H, Olesen J, Gonzales-Alonzo J, Bulow J, Kjaer M. Monitoring tissue oxygen availability with near infrared spectroscopy (NIRS) in health and disease. Scand J Med Sci Sports 2001;11:213-22.
  34. Mancini DM, Bolinger L, Li H, Kendrick K, Chance B, Wilson JR. Validation of near-infrared spectroscopy in humans. J Appl Physiol (1985) 1994;77:2740-7.
  35. Panagiotou M, Vogiatzis I, Louvaris Z, Jayasekera G, MacKenzie A, McGlinchey N, et al. Near infrared spectroscopy for the assessment of peripheral tissue oxygenation in pulmonary arterial hypertension. Eur Respir J 2016;48:1224-7.
  36. Dimopoulos S, Tzanis G, Karabinis A, Nanas S. Dynamic near-infrared spectroscopy assessment as an important tool to explore pulmonary arterial hypertension pathophysiology. Eur Respir J 2017 Jan 4;49(1):1602161.
  37. Dimopoulos S, Tzanis G, Manetos C, Tasoulis A, Mpouchla A, Tseliou E, et al. Peripheral muscle microcirculatory alterations in patients with pulmonary arterial hypertension: a pilot study. Respir Care 2013;58:2134-41.
  38. Fink C, Puderbach M, Bock M, Lodemann KP, Zuna I, Schmahl A, et al. Regional lung perfusion: assessment with partially parallel three-dimensional MR imaging. Radiology 2004;231:175-84.
  39. Hatabu H, Gaa J, Kim D, Li W, Prasad PV, Edelman RR. Pulmonary perfusion: qualitative assessment with dynamic contrast-enhanced MRI using ultra-short TE and inversion recovery turbo FLASH. Magn Reson Med 1996;36:503-8.
  40. Ley S, Kauczor HU. MR imaging/magnetic resonance angiography of the pulmonary arteries and pulmonary thromboembolic disease. Magn Reson Imaging Clin N Am 2008;16:263-73.
  41. Kreitner KF, Kunz RP, Ley S, Oberholzer K, Neeb D, Gast KK, et al. Chronic thromboembolic pulmonary hypertension - assessment by magnetic resonance imaging. Eur Radiol 2007;17:11-21.
  42. Kauczor HU, Ley-Zaporozhan J, Ley S. Imaging of pulmonary pathologies: focus on magnetic resonance imaging. Proc Am Thorac Soc 2009;6:458-63.
  43. Ohno Y, Hatabu H, Murase K, Higashino T, Kawamitsu H, Watanabe H, et al. Quantitative assessment of regional pulmonary perfusion in the entire lung using three-dimensional ultrafast dynamic contrast-enhanced magnetic resonance imaging: Preliminary experience in 40 subjects. J Magn Reson Imaging 2004;20:353-65.
  44. Anwar A, Ruffenach G, Mahajan A, Eghbali M, Umar S. Novel biomarkers for pulmonary arterial hypertension. Respir Res 2016;17:88.
  45. Dimitroulas T, Giannakoulas G, Papadopoulou K, Sfetsios T, Karvounis H, Dimitroula H, et al. Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis. Clin Rheumatol 2010;29:957-64.
  46. Dimitroulas T, Giannakoulas G, Sfetsios T, Karvounis H, Dimitroula H, Koliakos G, et al. Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford) 2008;47:1682-5.
  47. Giannakoulas G, Mouratoglou SA, Gatzoulis MA, Karvounis H. Blood biomarkers and their potential role in pulmonary arterial hypertension associated with congenital heart disease. a systematic review. Int J Cardiol 2014;174:618-23.
  48. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012;60:1249-56.
  49. Fenster BE, Lasalvia L, Schroeder JD, Smyser J, Silveira LJ, Buckner JK, et al. Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension. Heart Vessels 2016;31:939-46.
  50. Li LC, Li J and Gao J. Functions of galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther 2014;351:336-43.
  51. Malhotra R, Paskin-Flerlage S, Zamanian RT, Zimmerman P, Schmidt JW, Deng DY, et al. Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. Pulm Circ 2013;3:369-80.
  52. Tiede SL, Gall H, Dorr O, dos Santos Guilherme M, Troidl C, Liebetrau C, et al. New potential diagnostic biomarkers for pulmonary hypertension. Eur Respir J 2015;46:1390-6.
  53. Diller GP, van Eijl S, Okonko DO, Howard LS, Ali O, Thum T, et al. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation 2008;117:3020-30.
  54. Levy M, Bonnet D, Mauge L, Celermajer DS, Gaussem P, Smadja DM. Circulating endothelial cells in refractory pulmonary hypertension in children: markers of treatment efficacy and clinical worsening. PLoS One 2013;8:e65114.
  55. Smadja DM, Gaussem P, Mauge L, Israel-Biet D, Dignat-George F, Peyrard S, et al. Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 2009;119:374-81.
  56. Damico R, Kolb TM, Valera L, Wang L, Housten T, Tedford RJ, et al. Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2015;191:208-18.
  57. Kumpers P, Nickel N, Lukasz A, Golpon H, Westerkamp V, Olsson KM, et al. Circulating angiopoietins in idiopathic pulmonary arterial hypertension. Eur Heart J 2010;31:2291-300.
  58. Yang D, Liu Z, Yang Z. Ghrelin and its relation with N-terminal brain natriuretic peptide, endothelin-1 and nitric oxide in patients with idiopathic pulmonary hypertension. Cardiology 2013;124:241-5.
  59. Santos-Ferreira CA, Abreu MT, Marques CI, Goncalves LM, Baptista R, Girao HM. Micro-RNA Analysis in Pulmonary Arterial Hypertension: Current Knowledge and Challenges. JACC Basic Transl Sci 2020;5:1149-62.
  60. Sarrion I, Milian L, Juan G, Ramon M, Furest I, Carda C, et al. Role of circulating miRNAs as biomarkers in idiopathic pulmonary arterial hypertension: possible relevance of miR-23a. Oxid Med Cell Longev 2015;2015:792846.
  61. Perros F, Dorfmuller P, Montani D, Hammad H, Waelput W, Girerd B, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;185:311-21.